title: [Anti-HBV effects of genetically engineered replication-defective HBV with combined expression of antisense RNA and dominant negative mutants of core protein and construction of first-generation packaging cell line for HBV vector].
abstract: OBJECTIVE
  To explore the possibility of using HBV as a gene delivery vector, and to test the anti-HBV effects by intracellular combined expression of antisense RNA and dominant negative mutants of core protein.
  
  
  METHODS
  Full length of mutant HBV genome, which expresses core-partial P fusion protein and/or antisense RNA, was transfected into HepG2.2.15 cell lines. Positive clones were selected and mixed in respective groups with hygromycin in the culture medium. HBsAg and HBeAg, which exist in the culture medium, were tested by ELISA method. Intracellular HBc related HBV DNA was examined by dot blot hybridization. The existence of recombinant HBV virion in the culture medium was examined by PCR. Free of packaging signal, HBV genome, which express the HBV structural proteins including core, pol and preS/S proteins, was inserted into pCI-neo vector. HepG2 cell lines were employed to transfect with the construct. G418 selection was done at the concentration of 400mug/ml in the culture medium. The G418-resistant clones with the best expression of HBsAg and HBcAg were theoretically considered as packaging cell lines and propagated under the same conditions. It was transfected with plasmid pMEP-CPAS and then selected with G418 and hygromycin in the culture medium. The existence of recombinant HBV virion in the culture medium was examined by PCR.
  
  
  RESULTS
  The mean inhibitory rates of HBsAg were 2.74% 3.83%, 40.08 2.05% (t=35.5, P<0.01), 66.54% 4.45% (t=42.3, P<0.01), and 73.68% 5.07% (t=51.9, P<0.01) in group 2.2.15-pMEP4, 2.2.15-CP, 2.2.15-SAS, and 2.2.15-CPAS, respectively. The mean inhibitory rates of HBeAg were 4.46% 4.25%, 52.86% 1.32% (t=36.2, P<0.01), 26.36% 1.69% (t=22.3, P<0.01), and 59.28% 2.10% (t=39.0, P<0.01), respectively. The inhibitory rates of HBc related HBV DNA were 0, 82.0%, 59.9%, and 96.6%, respectively. Recombinant HB virion was detectable in the culture medium of all the three treatment groups. G418-resistant HBV packaging cell line, which harbored an HBV mutant whose packaging signal had been deleted, was generated. Expression of HBsAg and HBcAg was detectable. Transfected with plasmid pMEP-CPAS, it was found to secrete recombinant HB virion and no wild-type HBV was detectable in the culture medium.
  
  
  CONCLUSIONS
  It has stronger anti-HBV effects by combined expression of antisense RNA and dominant negative mutants than by individual expression of them. With the help of wild-type HBV, the modified HBV genome can form and secret HBV like particles, which provides evidence that the antiviral gene will be hepatotropic expression and the antiviral effects will be amplified. The packaging cell line can provide packaging for replication-defective HBV, but with low efficiency.
authors.affiliation: Institute of Liver Diseases, General Hospital of Beijing Military Region Beijing, Beijing 100700, China.
authors.forename: Dian Xing
authors.initials: DX
authors.lastname: Sun
authors.forename: Da Rong
authors.initials: DR
authors.lastname: Hu
authors.forename: Guang Hui
authors.initials: GH
authors.lastname: Wu
authors.forename: Xue Ling
authors.initials: XL
authors.lastname: Hu
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: Gong Ren
authors.initials: GR
authors.lastname: Fan
mesh_terms: D002460:Cell Line; D005818:Genetic Engineering; D005822:Genetic Vectors; D006515:Hepatitis B virus / Q000235:genetics*; D009154:Mutation; D010957:Plasmids; D016372:RNA, Antisense / Q000502:physiology*; D014162:Transfection; D014758:Viral Core Proteins / Q000502:physiology*; D019065:Virus Assembly; D014779:Virus Replication
chemical_list: D016372:RNA, Antisense; D014758:Viral Core Proteins